Indian Journal of Science and Technology

Open Access Open Access  Restricted Access Subscription Access

Erythropoietin may Modify Tyrosine Kinase Activity for its Neuroprotective Action in Mice


Affiliations
1 Department of Pharmacology,Christian Medical College, Vellore 632002, TN, India
 

The neuroprotective effect of erythropoietin (EpO) was evaluated against MgCl2 induced cerebral ischemia. EpO (500 IU/kg i.p) prevented the MgCl2 (0.5M) induced cerebral ischemia in the mice. EpO also reduced the bleeding time in mice by 7.64 %. Pretreatment with tyrosine kinase inhibitor, Genistein (6mg/kg i.p) attenuated the neuroprotective effect of EpO and reversed the effects of EpO on bleeding time in mice. These studies suggest that EpO is protective against MgCl2 induced cerebral ischemia and a role for tyrosine kinase enzyme in this action is suggested based on the results of this study.

Keywords

Tyrosine Kinase, Erythropoietin, Cerebral Ischemia, Mice
User

  • Akiyama T, Ishida J, Nakagawa S, Ogawara H , Watanabe S, Itoh N, Shibuya M and Fukami Y (1987) Genistein a specific inhibitor of Tyrosine specific protein kinases. J. Biol. Chem. 262, 5592-5595.

  • Bernaudin M, Marti HH, Roussel S, Divoux D, Neuvelot A, MacKenzie ET and Petit E (1999) A potential role for erythropoietin in focal permanent cerebral ischemia in mice, J. Cereb. Blood Flow Metab. 19, 643-651.

  • Callero MA, Pérez GM, Vittori DC, Pregi N and Nesse AB (2007) Modulation of protein tyrosine phosphatase 1B by erythropoietin in UT-7 cell line. Cell Physiol. Biochem. 20, 319-328.

  • Chong ZZ, Kang JQ & Maiese K (2002) Hematopoietic factor erythropoietin fosters neuroprotection through novel signal transduction cascades. J. Blood Flow & Metab. 22, 503-514.

  • Digicaylioglu M, Bichet S, Marti HH, Wenger RH, Rivas LA, Bauer C and Gassmann M (1995) Localization of specific erythropoietin binding sites in defined areas of the mouse brain. Proc. Natl. Acad. Sci. U.S. 92, 3717-3720.

  • Guo Z, Mizuno Y and Urabe T (2006) Intrinsic and extrinsic erythropoietin enhances neuroprotection against ischemia and reperfusion injury in vitro. J. Neurochem. 96, 1101-1110.

  • Ingley E (2009) CsK-binding protein can regulate Lyn signals controlling cell morphology. Int. J. Biochem. & Cell Biol. 41, 1332-1343.

  • Linnekin D, Evans GA, D’Andrea A and Farrar WL (1992) Association of the erythropoietin receptor with protein tyrosine kinase activity. Proc.Natl.Acad.Sci.U.S.A. 89, 6237-6241.

  • Lipsic E, Schoemaker RG, van der Meer P, Voors AA, van Veldhuisen DJ and van Gilst WH (2006) Protective effects of erythropoietin in cardiac ischemia: from bench to bedside. J Am Coll Cardiol. 48, 2161-2167.

  • Masuda S, Nagao M and Takahata K, Konishi Y, Gallyas F Jr, Tabira T, and Sasaki R (1993) Functional erythropoietin receptor of the cells with neural characteristics: Comparison with receptor properties of erythroid cells. J. Biochem. 268, 11208- 11216.

  • Miller BA, Bell LL, Lynch CJ and Cheung JY (1994) Erythropoietin modulation of intracellular calcium: a role for tyrosine phosphorylation. J. Cell Calcium. 16, 481-490.

  • Morris PE, Olmstead LE, Howard-Carroll AE, Dickens GE, Goltz ML, Carrie Courtney-Shapiro and Fanti P(1999) In Vitro and in vivo effects of genistein on murine alveolar macrophage TNFa production. Inflamm. 23, 231-239.

  • Ruscher K, Freyer D, Karsch M, Isac N, Megow D, Sawitzki B, Priller J, Dirnagl U and Meisel A (2002) Erythropoietin is a paracrine mediator of ischemic tolerance in the Brain: Evidence from an in vitro model.The J. Neurosci. 22, 10291- 10301.

  • Tyagi MG and Namboodri KV (2005) Evaluation of vasopressin mediated effects on hemostatic mechanisms: Relationship with aquaporins and caveolin proteins. Indian J. Exp. Biol. 43, 710-714.

  • Tyagi MG and Parthiban KV (2003) Vasopressin mediates neuroprotection in mice by stimulation of V1 Vasopressin receptors: Influence of PI-3 Kinase and gap junction inhibitors. Ind. J. Exp. Biol. 41, 574-580.

  • van der Kooij MA, Groenendaal F, Kavelaars A, Heijnen CA and van Bel F (2008) Neuroprotective properties and mechanisms of erythropoietin in vitro and in vivo experimental models for hypoxia/ischemia. Brain Res.Rev. 59, 22-33.

  • Vink R and Cernak I (2000) Regulation of intra cellular free magnesium in central nervous system injury. Front. Biosci. 5, 256.

  • Yenari M, Kitagawa K, Lyden P & Perez-Pinzon M (2008) Metabolic downregulation: a key to successful neuroprotection? Stroke. 39, 2910-2917.


Abstract Views: 380

PDF Views: 95




  • Erythropoietin may Modify Tyrosine Kinase Activity for its Neuroprotective Action in Mice

Abstract Views: 380  |  PDF Views: 95

Authors

M. G. Tyagi
Department of Pharmacology,Christian Medical College, Vellore 632002, TN, India

Abstract


The neuroprotective effect of erythropoietin (EpO) was evaluated against MgCl2 induced cerebral ischemia. EpO (500 IU/kg i.p) prevented the MgCl2 (0.5M) induced cerebral ischemia in the mice. EpO also reduced the bleeding time in mice by 7.64 %. Pretreatment with tyrosine kinase inhibitor, Genistein (6mg/kg i.p) attenuated the neuroprotective effect of EpO and reversed the effects of EpO on bleeding time in mice. These studies suggest that EpO is protective against MgCl2 induced cerebral ischemia and a role for tyrosine kinase enzyme in this action is suggested based on the results of this study.

Keywords


Tyrosine Kinase, Erythropoietin, Cerebral Ischemia, Mice

References





DOI: https://doi.org/10.17485/ijst%2F2010%2Fv3i1%2F29657